AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

NASDAQ:OMEROmeros Stock Price, Forecast & News

$14.95
+0.04 (+0.27 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.74
Now: $14.95
$15.26
50-Day Range
$13.56
MA: $15.17
$16.99
52-Week Range
$8.50
Now: $14.95
$20.92
Volume219,612 shs
Average Volume681,712 shs
Market Capitalization$814.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PDE10 (OMS824) which is in Phase II clinical trial for treating Huntington's disease and schizophrenia; PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is based in Seattle, Washington.
Read More
Omeros logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:OMER
CUSIP68214310
Phone206-676-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$111.81 million
Book Value($2.19) per share

Profitability

Net Income$-84,490,000.00

Miscellaneous

Employees236
Market Cap$814.94 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Omeros (NASDAQ:OMER) Frequently Asked Questions

How has Omeros' stock been impacted by COVID-19 (Coronavirus)?

Omeros' stock was trading at $15.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OMER stock has decreased by 0.6% and is now trading at $14.95. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Omeros?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Omeros.

When is Omeros' next earnings date?

Omeros is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Omeros.

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) issued its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.19. The biopharmaceutical company had revenue of $23.54 million for the quarter, compared to analysts' expectations of $30.92 million. View Omeros' earnings history.

What price target have analysts set for OMER?

4 equities research analysts have issued 1-year price objectives for Omeros' shares. Their forecasts range from $17.00 to $34.00. On average, they anticipate Omeros' stock price to reach $25.33 in the next year. This suggests a possible upside of 69.5% from the stock's current price. View analysts' price targets for Omeros.

Has Omeros been receiving favorable news coverage?

Press coverage about OMER stock has trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Omeros earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutOmeros.

Who are some of Omeros' key competitors?

What other stocks do shareholders of Omeros own?

Who are Omeros' key executives?

Omeros' management team includes the following people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 60)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 61)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 59)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 56)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 62)

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

Who are Omeros' major shareholders?

Omeros' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.79%), Cormorant Asset Management LP (4.63%), State Street Corp (2.13%), Cpwm LLC (1.28%), UBS Group AG (0.93%) and Atom Investors LP (0.55%). Company insiders that own Omeros stock include Marcia S Kelbon and Thomas J Cable. View institutional ownership trends for Omeros.

Which institutional investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Morgan Stanley, Morgan Stanley, D.A. Davidson & CO., Tudor Investment Corp Et Al, Hohimer Wealth Management LLC, Cpwm LLC, and United Capital Financial Advisers LLC. View insider buying and selling activity for Omeros.

Which institutional investors are buying Omeros stock?

OMER stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, BlackRock Inc., Atom Investors LP, State Street Corp, Two Sigma Investments LP, Trexquant Investment LP, Squarepoint Ops LLC, and Balyasny Asset Management LLC. View insider buying and selling activity for Omeros.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $14.95.

How big of a company is Omeros?

Omeros has a market capitalization of $814.94 million and generates $111.81 million in revenue each year. The biopharmaceutical company earns $-84,490,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Omeros employs 236 workers across the globe.

What is Omeros' official website?

The official website for Omeros is www.omeros.com.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.